At the inauguration ceremony (from left): Terry Hermiston, Site Head for the U.S. Innovation Center, Andreas Fibig, Chairman of the Board of Management, Bayer Schering Pharma, and Prof. Andreas Busch, Head of Global Drug Discovery, BSP.
Bayer Celebrates the Grand Opening of the U.S. Innovation Center
Leverkusen, January 2011. Early this week, representatives
from state and local government, academia and the biotech sector joined Bayer employees at the U.S.
Innovation Center to commemorate the official opening of Bayer’s newest research facility. The
reception’s theme, "Building a Bright Future," was brought to life as Bayer leaders and guest
speakers placed puzzle pieces symbolizing the need to work together into an art piece, which was
lit to signify the bright future for Bayer and its partners in one of the fastest growing life
sciences communities – Mission Bay.
Building a Bright Future Andreas Fibig, Chairman of the Board of Management for Bayer Schering Pharma,
Prof. Andreas Busch, Head of Global Drug Discovery, BSP, and Terry Hermiston, Vice President of
U.S. Biologics Research and Site Head for the U.S. Innovation Center, spoke of the decision to
locate in San Francisco and announced Bayer’s new master agreement with the University of
California, San Francisco, which provides a framework for efficient research collaborations between
the two organizations moving forward.
“Making the decision to locate our U.S. Innovation Center here at Mission Bay was an easy
one – it put us next to one of the campuses of the most prolific research institutions in the
nation – the University of California,” said Hermiston. “Here, we have the great fortune to
interact with nationally and internationally renown scientists.”
Keith Yamamoto, PhD, Executive Vice Dean of the UCSF School of Medicine, extolled the
audience of roughly 200 on the value of this new academic/industry collaboration and the
mutually-beneficial research projects to come. Joining Yamamoto in welcoming Bayer to Mission Bay
were: Gail Maderis, President, BayBio; Joel Ayala, Director, Governor’s Office of Economic
Development; and Todd Rufo, Director of Economic Development for San Francisco.
"Bayer chose San Francisco as the site for its U.S. Innovation Center because of the leading
role this area’s research community plays in life science discovery,” said Fibig. “The master
agreement with UCSF sets the stage for a long and successful public-private partnership which
builds our pipeline and brings novel medicines to patients.”
In addition, Bayer’s move from Richmond also provided us with the opportunity to donate $2
million in lab equipment and office supplies to roughly a dozen schools, colleges and universities
to support science education.
“As a research-driven organization, scientific innovation has been the cornerstone of Bayer’s
business growth for close to 150 years. Every great product on the market and promising product
candidate in our pharmaceutical portfolio starts with exceptional science,” said Fibig. “Here at
the U.S. Innovation Center, we’ve created laboratories for scientists to collaborate in a variety
of disciplines. We’ve specifically charged our U.S. Research Team with a new responsibility to “
bring the outside in” – new ideas, new technologies, new discoveries and new partners – to become a
“science hub.”
“Scientists in Bayer’s Global Drug Discovery organization share a common purpose – to serve
patients and improve health care around the world,” said Busch. “For researchers to do their best
work, it starts with an environment that encourages engagement in the larger scientific community.
Our decision to place Bayer’s U.S. Innovation Center here at Mission Bay places our researchers in
what I view as the center of life science innovation in America.”